Navigation Links
American Society of Breast Surgeons Release MammoSite Breast Brachytherapy Registry Trial Final Results
Date:10/2/2013

BEDFORD, Mass., Oct. 2, 2013 /PRNewswire/ -- Hologic, Inc. (Hologic or the Company) (NASDAQ: HOLX), a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products, with an emphasis on serving the healthcare needs of women, today announced that the final analysis of the American Society of Breast Surgeons (ASBS) MammoSite Breast Brachytherapy Registry Trial data confirms previously noted "excellent" results and compares favorably with other forms of accelerated partial breast irradiation (APBI) and with outcomes seen in patients treated with whole breast irradiation with similar follow-up.[i] The final analysis was published online in advance of print in the August 22, 2013 issue of the Annals of Surgical Oncology.

The seven year MammoSite Registry Trial followed over 1,400 patients who were diagnosed with early stage breast cancer and underwent breast conserving therapy, which included treatment with Hologic's MammoSite targeted radiation therapy system, between May 2002 and June 2004. By employing MammoSite Therapy, the radiation oncologist can deliver targeted radiation therapy directly to the area where cancer is most likely to recur, allowing a full course of radiation to be delivered in just five days as compared to five to seven weeks. The final analysis demonstrates low rates of local recurrence, long-term cosmesis of greater than 90% and toxicity rates of less than 10%.ii

"The American Society of Breast Surgeons MammoSite Registry Trial continues to represent one of the most pivotal studies available in defining the safety and efficacy of brachytherapy based partial breast irradiation," said Dr. Chirag Shah of Summa Health System and lead author on the paper. "With over 1,400 patients treated and follow-up exceeding five years, it is the only brachytherapy study with over 1,000 patients accrued and five year follow-up available at this time. The final analysis of this trial not only confirmed the efficacy of brachytherapy based partial breast irradiation, but demonstrated that rates of toxicity following treatment remain low and favorable, in line with previously reported toxicity rates using whole breast irradiation." 

"We are pleased that patient outcomes remained strong and comparable to other radiation treatment options throughout the length of the study," said Carter Houghton, Hologic's Senior Vice President and General Manager, Interventional Breast Solutions. "The acceptance of accelerated partial breast irradiation as an effective treatment option for women diagnosed with early stage breast cancer continues to grow worldwide due in part to the favorable results reported throughout this study. Hologic's MammoSite Radiation Therapy is a compassionate treatment option that allows women to return to their daily activities after just five days of treatment, as compared to the conventional five to seven weeks, while minimizing side effects such as skin burning and fatigue."

About MammoSite Targeted Radiation TherapyBy employing MammoSite Therapy, the radiation oncologist can deliver targeted radiation therapy directly to the area where cancer is most likely to recur, allowing a full course of radiation to be delivered in just five days as compared to five to seven weeks. Additionally, targeted therapy of the breast limits radiation exposure to normal, healthy tissue minimizing side effects such as skin discoloration, scarring, burning, fatigue and damage to surrounding organs. With its multi-lumen design, the MammoSite ML system gives radiation oncologists the ability to adjust the radiation dose for typical cases and treat patients who are otherwise not appropriate candidates for traditional brachytherapy. First cleared for sale by the FDA in 2002, MammoSite is the most widely utilized and accepted method of APBI in the United States.

About Hologic, IncHologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems, and surgical products, with an emphasis on serving the healthcare needs of women. The Company operates four core business units focused on breast health, diagnostics, GYN surgical and skeletal health. With a comprehensive suite of technologies and a robust research and development program, Hologic is committed to improving lives. The Company is headquartered in Massachusetts.

Hologic, MammoSite and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.

Forward-Looking Statement DisclaimerThis News Release may contain forward-looking information that involves risks and uncertainties, including statements about the use of the Hologic MammoSite system. There can be no assurance the system will achieve the benefits described herein and that such benefits will be replicated in any particular manner with respect to an individual patient as the actual effect of the use of the MammoSite system can only be determined on a case-by-case basis depending on the particular circumstances and patient in question. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to the data or statements presented herein to reflect any change in the Company's expectations or any change in events, conditions or circumstances on which any such data or statements are based.

ContactsMarianne McMorrow

Greg AmanteCorporate Marketing

Interventional Breast SolutionsHologic, Inc.

Hologic, Inc.Marianne.McMorrow@hologic.com  

Greg.Amante@hologic.com Tel: +1 781 999 7723

Tel: +1 508 263 8487[i],[ii] Shah C, Badiyan S, Ben Wilkinson J, Vicini F, Beitsch P, Keisch M, Arthur D, Lyden M. Treatment Efficacy with Accelerated Partial Breast Irradiation (APBI): Final Analysis of the American Society of Breast Surgeons MammoSite(®) Breast Brachytherapy Registry Trial. Ann Surg Oncol. 2013 Aug 22. [Epub ahead of print] PubMed PMID: 23975302


'/>"/>
SOURCE Hologic, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Simeprevir Data in Hepatitis C Patients to be Presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
2. Warnings for Hepatitis B Reactivation in Cancer Patients Welcomed by the American Association for the Study of Liver Diseases
3. Micell Technologies Announces DESSOLVE I Manuscript Accepted for Publication in American College of Cardiologys Cardiovascular Interventions Journal
4. Philips Showcases Innovations in Radiation Oncology Imaging Technology and Workflow Planning at the 55th American Society for Radiation Oncology (ASTRO) Annual Meeting
5. Unique Glaucoma Test Through Eyelid DIATON Opens Doctors Eyes to Possibility of In-Office Glaucoma Test at Pri-Med East and American Academy of Family Physicians, AAFP
6. American Cancer Society Expands Efforts to Reduce Burden of Cancer in Underserved Communities
7. Jeannette R. Jakus, MD, MBA, Awarded American Academy of Dermatology Translational Biotechnology Fellowship
8. PAREXEL International To Present At Robert Baird Healthcare Conference And Raymond James North American Equities Conference
9. Edison expands North American healthcare sector coverage with initiation of coverage on Alexza Pharmaceuticals
10. Kansas Ride for the Red to Benefit American Red Cross Chapter
11. Study of Mechanism of Action of Ibrutinib in Mantle Cell Lymphoma Published in Blood - Journal of the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Research and Markets has announced the addition of the ... to 2022" report to their offering. ... financial data derived from varied research sources to present unique ... on the market during the next five years, including a ... markets, regional and country level analysis. The report provides a ...
(Date:6/23/2016)... , June 23, 2016 Research ... Pharma News Issue 52" report to their offering. ... in influenza treatment creates a favourable commercial environment for MedImmune ... growing patient base that will serve to drive considerable growth ... vaccine would serve to cap sales considerably, but development is ...
(Date:6/23/2016)... VIEW, Calif. , June 23, 2016 ... a.m. CST on Thursday, July 7, 2016 , , , ... kayla.belcher@frost.com ) , , , , EXPERT PANELISTS:  , ... Nitin Naik; Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa ... The global pharmaceutical industry is witnessing an ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... Many women ... diagnosed with endometriosis. These women need a treatment plan to not only alleviate ... that can help for preservation of fertility and ultimately achieving a pregnancy. The ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room ... Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of ...
(Date:6/24/2016)... , ... June 24, 2016 , ... A recent ... most people are unfamiliar with. The article goes on to state that individuals are ... many of these less common operations such as calf and cheek reduction. The Los ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that ... chosen by their peers for this recognition are considered among the top 2 percent ... special honors as members of this year’s Legal Elite Hall of Fame: Miami ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented ... in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor the ... Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With this award, ...
Breaking Medicine News(10 mins):